Macrogenics, Inc.

Rockville, MD 20850

Market Performance

NASDAQ: MGNX
Market Cap $728 Million
52 Week High $31.85
52 Week Low $14.36

SBIR Award Summary

Total Number of Awards 13
Total Value of Awards $2.7MM
First Award Date 09/30/02
Most Recent Award Date 09/01/04

Key Personnel

Last Name Name Awards Contact
Stavenhagen Jeffrey B Stavenhagen 4
Johnson Leslie S Johnson 2
Ferguson Stacy E. Ferguson 1
Nordstrom Jeffrey L Nordstrom 1
Rankin Christopher T Rankin 2
Von Haller Priska Von 1
Tjoelker Larry Tjoelker 1
Schummer Michel Schummer 1

13 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/04 - 08/31/05

DESCRIPTION (provided by applicant): Tumor specific therapeutic antibodies direct the immune system to eliminate or prevent growth of tumor cells. Passive and active humoral immune responses are mediated via interactions between the IgG Fc domain and specific Fc receptors (FcR) present on the surfaces of effector cells. Proof of principal exper...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PAS-02-149
Budget: 07/15/04 - 12/31/05

DESCRIPTION (provided by applicant): The long-term objective of this work is to eliminate brucellosis as a biothreat. Brucella infection may occur through water, food sources and through exposure to infected animals. Brucella species induce abortions in domestic animals and severe, incapacitating illness in humans, with symptoms of undulating f...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/04 - 06/30/05

DESCRIPTION (provided by applicant): One of the main mechanisms by which clinically approved anti-cancer antibodies, Herceptin and Rituxan, mediate their anti-tumor effect is by antibody-dependent cell-mediated cytotoxicity (ADCC) 1,2,3. In a xenograft model in mice deficient in the inhibitory Fc-gammaRIIB4, Herceptin demonstrated substantial...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/04 - 03/31/05

DESCRIPTION (provided by applicant): Recent studies have revealed the importance of Fc receptors, especially FcRIII in mediating the pathogenic effects of autoantibodies. Murine monoclonal antibodies against FcRIII have been demonstrated to be effective in blocking the interaction of this receptor with immune complexes. This blocking activity h...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/04 - 03/31/05

DESCRIPTION (provided by applicant): The overall objective of this proposal is to identify, in serum and urine samples from melanoma patients, specific marker proteins or patterns of protein expression, which are diagnostic of cancer. As with many malignancies, early detection is critical for successful treatment of melanoma. Recent innovations ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 02/01/04 - 01/31/05

DESCRIPTION (provided by applicant): The interaction of immune complexes or opsonized cells containing pathogenic autoantibodies with Fc-receptors on effector cells leads to cellular depletion, inflammation and tissue damage depending on the target of the antibody. The current proposal is based on the hypothesis that soluble Fcgamma-receptors (...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/03 - 08/31/04

DESCRIPTION (provided by applicant): Tumor specific therapeutic antibodies direct the immune system to eliminate or prevent growth of tumor cells. Passive and active humoral immune responses are mediated via interactions between the IgG Fc domain and specific Fc receptors (FcR) present on the surfaces of effector cells. Proof of principal exper...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/03 - 08/31/04

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PAS-02-149
Budget: 09/15/03 - 09/14/05

DESCRIPTION (provided by applicant): Glanders is a severe disease that has already been used as a bioweapon. It is naturally an equine disease but can be administered by aerosol for efficient human infection. Even if quickly diagnosed as Burkholderia mallei and treated, antibiotics do not control infections well. No vaccine has been developed, y...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/03 - 07/31/04

DESCRIPTION (provided by applicant): Cutaneous T-cell lymphoma (CTCL) affects 5000 cases in the United States every year, 20% of which will present with a poor prognosis and a mean survival of 3 years. Despite the impact of biological response modifiers, such as interferon alpha, there still remains up to 25 to 50% of patients who present with a...

Load More